Crushing disappointment is not an uncommon occurrence in the stock market, but it is practically commonplace in the biotech sector. For every Gilead Sciences (Nasdaq: GILD) or Celgene (Nasdaq: CELG), there are many companies whose compounds fail and whose stocks wither away to mere penny prices.

That said, biotech may also be one of the resilient sectors you can find. So long as you still have a few compounds (or a few ideas) and enough cash, you will get a second chance. And if that second chance works out, you will find the market is more than willing to let bygones be bygones.

IN PICTURES: 5 "New" Rules For Safe Investing

Nervous Neurocrine
I decided to write this column when I saw news last week that Neurocrine Biosciences (Nasdaq: NBIX) signed a partnership agreement with Abbot Labs for its promising endometriosis drug (Elagolix). This agreement gives Neurocrine $75 million up front, potentially $500 million more in milestones, and royalties on future sales (probably in the teens) that could be in excess of $350 million if the drug also gets approved for fibroids.

Not so long ago, Neurocrine was all but left for dead when its once-promising sleep aid Indiplon reached a dead end. Just last week, though, the company reached two licensing agreements (the Abbott deal and a separate second deal with Boehringer for certain small agonists relating most prominently to diabetes), and it should have the cash to advance a pipeline that is promising, though at quite an early stage.

Isis And D'Nile
Isis Pharmaceuticals (Nasdaq: ISIS) has certainly known the thrill of (presumed) victory and the agony of defeat. One of the pioneers in antisense technology, Isis has been buffeted by years of clinical failures. Though Isis had once-promising drug candidates for two of the Holy Grails in biotech - inflammatory disease and cancer - they largely all flamed out, and only one drug ever made it to market. Worse yet, that one drug (Vitravene) has been inconsequential in the market.

Still, Isis gamely pressed on and continued to develop its technology. Now the company has a promising cholesterol drug (mipomersen) licensed to Genzyme (Nasdaq: GENZ) and a robust pipeline of drugs, including promising medications for inflammatory disease, cardiovascular disease, diabetes and cancer, as well as numerous partnerships. All in all, by virtue of always having cash (or access to cash) and always trying to push the technology forward, Isis has stayed in the game and could still become the pioneer in antisense technology.

Success Without Success
Let us also consider the case of Vivus (Nasdaq: VVUS) and Nektar (Nasdaq: NKTR). Both of these companies had drugs actually reach the market (though Nektar's position was that of licensor), but both were exceptionally disappointing. Vivus's original erectile dysfunction drug (MUSE) was buried by the likes of Viagra and Cialis, no doubt due in part to a cringe-inducing administration method, while Nektar's involvement in inhaled insulin came a cropper when Pfizer quickly abandoned Exubera. (For more, see The UPs And Downs Of Biotechnology.)

Nevertheless, both companies are now enjoying a second bite at the apple. Vivus has a promising drug for obesity (Qnexa) that should hit the market this year and could reap hundreds of millions in sales. Nektar is not so close to market with its own proprietary drugs (the company still has numerous development deals with other pharmaceutical companies), but its cancer drug NKTR-102 has shown promising data in early trials and could become a major player in time.

Never Say Die
None of the companies discussed in this column have really "made it" yet. What I think is important, though, is to appreciate that a company with sufficient cash and promising compounds in the pipeline can rebound from seemingly devastating setbacks. This is why I am adamant about investors searching out those biotech companies with ample cash on the balance sheet and at least two separate drug development programs (that is, two entirely different compounds, not one compound being developed for two different conditions).

It is inevitable that the majority of biotech drug candidates will fail. What is not so inevitable, though, is that the company itself must fail and that shareholders will be left with nothing. If investors can spend the time to seek out those companies with multiple opportunities for success and diversify their holdings to spread the risk, they too can navigate the tricky minefield of biotech without getting blown up. (For related reading, see Using DCF In Biotech Valuation.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  3. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  4. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  5. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  6. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  7. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  8. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
  9. Mutual Funds & ETFs

    3 Vanguard Equity Fund Underperformers

    Discover three funds from Vanguard Group that consistently underperform their indexes. Learn how consistent most Vanguard low-fee funds are at matching their indexes.
  10. Investing News

    Alphabet Earnings Beat Expectations (GOOGL, AAPL)

    Alphabet's earnings crush analysts' expectations; now bigger than Apple?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
Trading Center